Articles Use of 18FFDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2positive breast cancer and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in 18FFDG PETpredicted nonresponders AVAT
Bioportfolio,
In patients with HER2positive breast cancer early PET assessment can help to identify nonresponders to neoadjuvant docetaxel…